Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Net Cash Flow (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Net Cash Flow for 7 consecutive years, with $594339.0 as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 106.44% to $594339.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 118.7% increase, with the full-year FY2025 number at -$6.8 million, up 19.14% from a year prior.
  • Net Cash Flow was $594339.0 for Q4 2025 at Outlook Therapeutics, up from -$817729.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $1.9 million in Q1 2025 to a low of -$9.2 million in Q4 2024.